{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981468351019136.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.23190"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.23190"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200909000-00001"}}],"dc:title":[{"@value":"Chronic hepatitis B: Update 2009 #"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981468351019136","@type":"Researcher","foaf:name":[{"@value":"Anna S. F. Lok"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468351019137","@type":"Researcher","foaf:name":[{"@value":"Brian J. McMahon"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2009-09","prism:volume":"50","prism:number":"3","prism:startingPage":"661","prism:endingPage":"662"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.23190"},{"@id":"https://journals.lww.com/01515467-200909000-00001"}],"createdAt":"2009-07-28","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002215326388096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002218323019648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231260693376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231298215040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231534036352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Future therapy for hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232067135360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232550463616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interferon-α suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235524189696","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sequential analysis of amino acid substitutions with hepatitis <scp>B</scp> virus in association with nucleoside/nucleotide analog treatment detected by deep sequencing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757608832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Case treated with triple therapy of lamivudine, interferon‐β and prednisolone for acute exacerbation of chronic hepatitis B during pregnancy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239632624640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283695737457280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714664842368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166783165952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182167613312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185445755776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185710649216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Recommendation of lamivudine‐to‐entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588379362813696","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sex and ethnic disparities in hepatitis B evaluation and treatment across the world"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256755584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640991098880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643093195008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846645717180288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687497728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment of chronic hepatitis B with nucleos(t)ide analogues"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664146523648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664563123328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prophylactic managements of hepatitis B viral infection in liver transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567389384960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707377081472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204793323648","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of resolved hepatitis B who was observed HBV viremia transiently during HSV hepatitis immediately after steroid pulse therapy"},{"@language":"ja","@value":"ステロイドパルス療法直後に単純ヘルペスウイルス肝炎を発症し，一過性に血中B型肝炎ウイルスDNAの陽性化を認めたB型肝炎ウイルス既往感染者の1例"},{"@value":"症例報告 ステロイドパルス療法直後に単純ヘルペスウイルス肝炎を発症し,一過性に血中B型肝炎ウイルスDNAの陽性化を認めたB型肝炎ウイルス既往感染者の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク ステロイドパルス リョウホウ チョクゴ ニ タンジュンヘルペスウイルス カンエン オ ハッショウ シ,イッカセイ ニ ケッチュウ Bガタ カンエンウイルス DNA ノ ヨウセイカ オ ミトメタ Bガタ カンエンウイルス キオウ カンセンシャ ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204875749376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390007216692494208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A systematic study of <i>Tupaia</i> as a model for human acute          hepatitis B infection"},{"@value":"A systematic study of Tupaia as a model for human acute hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770184960","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Three cases of chronic hepatitis B in that interferon therapy was indicated"},{"@value":"インターフェロン治療を行ったB型慢性肝炎の3例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク インターフェロン チリョウ オ オコナッタ Bガタ マンセイ カンエン ノ 3レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770442112","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"保存的治療にて救命し得たラミブジン誘発横紋筋融解症合併B型慢性肝炎急性増悪の1例"},{"@language":"en","@value":"Conservative treatment of lamivudine-induced rhabdomyolysis in a patient with acute exacerbation of chronic hepatitis B"},{"@value":"症例報告 保存的治療にて救命し得たラミブジン誘発横紋筋融解症合併B型慢性肝炎急性増悪の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク ホゾンテキ チリョウ ニテ キュウメイ シエタ ラミブジン ユウハツ オウモンキン ユウカイショウ ガッペイ Bガタ マンセイ カンエン キュウセイ ゾウアク ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772498432","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"肝発癌後にPeg-IFNα-2a投与によりHBs抗原陰性化；HBs抗体陽性化が得られたB型慢性肝炎の1例"},{"@language":"en","@value":"Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFNα-2a treatment after surgery for hepatocellular carcinoma: a case report"},{"@value":"症例報告 肝発癌後にPeg-IFNα-2a投与によりHBs抗原陰性化 : HBs抗体陽性化が得られたB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク カンハツガン ゴ ニ Peg-IFNa-2a トウヨ ニ ヨリ HBs コウゲン インセイカ : HBs コウタイ ヨウセイカ ガ エラレタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238083548032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Receptor-Interacting Protein Kinase 3 (RIPK3) mRNA Levels Are Elevated in Blood Mononuclear Cells of Patients with Poor Prognosis of Acute-on-Chronic Hepatitis B Liver Failure"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.23190"},{"@type":"CROSSREF","@value":"10.1007/s00535-010-0367-5_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.00998.x_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1007/s00535-014-1010-7_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1007/s10147-011-0294-3_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1007/s12328-015-0590-y_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/hepr.12168_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.01077.x_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3748/wjg.v20.i34.12031_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.51_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.2957/kanzo.57.666_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1016/j.cmi.2016.12.014_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3748/wjg.v22.i1.262_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.853_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1016/j.imlet.2014.03.013_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1038/s41598-017-14747-5_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/cei.12259_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00807.x_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1016/j.virol.2012.07.002_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.2957/kanzo.56.341_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1292/jvms.21-0026_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3851/imp2777_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2024.02.033_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1168-2_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/hepr.12902_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00921.x_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3109/14397595.2013.852834_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3748/wjg.v22.i1.165_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.56.8233_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1016/j.leukres.2016.09.014_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3390/v12080840_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1620/tjem.247.237_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.1111/hepr.13768_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"},{"@type":"CROSSREF","@value":"10.3892/br.2017.944_references_DOI_7w2z5VQAsU0OSh85Pftb0GlUIhC"}]}